SCHEMBL21588367

SCHEMBL21588367

CC(C)(C)OC(=O)N1CCc2c([nH]c3ccc(F)cc23)C1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.58
TRPV1 Q8NER1 11/20 0.56
BRD3 Q15059 2/20 0.53
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 1/20 0.49
ALDH1A1 P00352 1/20 0.49
MAPT P10636 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
KMT2A Q03164 1/20 0.49
HSD17B10 Q99714 1/20 0.49
FAAH O00519 1/20 0.49
CDK4 P11802 2/20 0.48
CCND1 P24385 2/20 0.48
CFTR P13569 1/20 0.48
LMNA P02545 1/20 0.47
PABPC1 P11940 1/20 0.47
ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5104575 0.91 BAZ2B (0.71) BAZ2BBRD3SMN1; SMN2KDM4EMEN1
SCHEMBL21588267 0.91 TRPV1 (0.51) BAZ2BTRPV1BRD3FAAHCDK4
SCHEMBL21154458 0.90 BAZ2B (0.59) BAZ2BTRPV1BRD3SMN1; SMN2KDM4E
SCHEMBL10127727 0.87 BAZ2B (0.62) BAZ2BBRD3SMN1; SMN2KDM4EMEN1
SCHEMBL30147601 0.87 PARP1 (0.49) BAZ2BTRPV1BRD3CDK4CCND1
SCHEMBL30981939 0.87 BAZ2B (0.58) BAZ2BTRPV1SMN1; SMN2ALDH1A1MAPT
SCHEMBL11433133 0.87 BAZ2B (0.58) BAZ2BTRPV1SMN1; SMN2ALDH1A1MAPT
SCHEMBL3722389 0.87 BAZ2B (0.58) BAZ2BTRPV1SMN1; SMN2MEN1MAPT
SCHEMBL21588257 0.86 BAZ2B (0.61) BAZ2BTRPV1ALOX15TSHRHSD17B10
SCHEMBL1780524 0.86 TRPV1 (0.55) TRPV1SMN1; SMN2MAPTKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2023-08-17 US disclosed
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2023-08-17 US disclosed
US-11684625-B2 Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates AC IMMUNE SA (CH) 2023-06-27 US disclosed
US-11684625-B2 Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates AC IMMUNE SA (CH) 2023-06-27 US disclosed
WO-2019233883-A1 TETRAHYDROBENZOFURO[2,3-C]PYRIDINE AND BETA-CARBOLINE COMPOUNDS FOR THE TREATMENT, ALLEVIATION OR PREVENTION OF DISORDERS ASSOCIATED WITH TAU AGGREGATES AC IMMUNE SA (CH) 2019-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates MAPT, MAP1LC3A, MAP1LC3B BAZ2B 1307/4885TRPV1 3673/4885BRD3 752/4885
US-11684625-B2 Compounds for the treatment, alleviation or prevention of disorders associated with tau aggregates MAPT, PSEN2, PSEN1 BAZ2B 2402/4885TRPV1 4131/4885BRD3 1772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.